May Health Announces CE Mark for Innovative Treatment for Women with PCOS-related Infertility
May Health, a medical device company dedicated to helping women living with polycystic ovary syndrome (PCOS), today announced that its novel technology to treat PCOS-related infertility, the Anavi™ System, has received CE Mark certification. The CE Mark, granted under the European Union’s Medical Device Regulation (EU MDR) 2017/745, is a significant regulatory milestone that enables commercialization in the European Union.
May Health Raises $25 Million in Series B Funding to Advance Development for Ovarian Rebalancing Therapy
May Health, a clinical-stage medical device company dedicated to helping those living with the endocrine disorder polycystic ovary syndrome (PCOS), today announced it has closed a $25 million Series B financing round, co-led by Bpifrance and Trill Impact with participation from founding investor Sofinnova Partners, as well as Avestria Ventures and Kidron Capital Assets LP. Funds will be used to support the company’s growth and advance its Ovarian Rebalancing™ therapy through the pivotal REBALANCE Study, evaluating its potential to address PCOS-related infertility.
May Health Announces Data From Feasibility Studies of its Novel Ovarian Rebalancing™ Treatment and Receives Approval From FDA for Pivotal Trial
May Health, a clinical-stage medical device company dedicated to helping those living with the endocrine disorder polycystic ovary syndrome (PCOS), today announced new clinical trial results providing preliminary data supporting the safety and effectiveness of its Ovarian Rebalancing™ treatment for inducing ovulation in women with PCOS-related infertility. Early outcomes data from the ULTRA-EU and ULTRA-US feasibility clinical trials were presented at the 39th Annual ESHRE meeting in Copenhagen, Denmark on June 26, 2023.
May Health Solidifies Veteran Executive Team with Appointment of Women’s Health Care Leader Anne Morrissey as CEO
May Health, a clinical-stage medical device company dedicated to helping those living with the endocrine disorder polycystic ovary syndrome (PCOS), today announced it is changing its name from AblaCare to May Health, and has solidified its executive team with Anne Morrissey as CEO and Dr. Robert Auerbach, OBGYN, as chairman of the board. Morrissey, an experienced executive who was previously CEO of Alydia Health, will lead May Health as it investigates its novel Ovarian Rebalancing™ technology, a one-time, transvaginal ablation procedure designed to activate natural ovulation for those with PCOS, a leading cause of infertility.
